Tryp Therapeutics, a development-stage pharmaceutical company focused on psilocybin and other treatments, will begin trading on the Canadian Stock Exchange (CSE) today under the symbol “TRYP”. After initially attempting to sell 17.4 million units at $0.25 to investors, the company said Monday it would fully exercise its over-allotment option, increasing the total number of units…